Thyroid hormone receptor β1 domains responsible for the antagonism with the ras oncogene: Role of corepressors

Oncogene

Volumn 30, Issue 7, 2011, Pages 854-864

  Garcia Silva S ^a   Martinez Iglesias O ^a   Ruiz Llorente, L ^a   Aranda, A ^a  

^a CSIC   (Spain)

Author keywords

coactivators; corepressors; cyclin D1; Ras; thyroid hormone receptor; transformation

Indexed keywords

COREPRESSOR PROTEIN; CYCLIN D1; SMALL INTERFERING RNA; THYROID HORMONE RECEPTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CO-REPRESSOR PROTEINS; CYCLIN D1; GENES, RAS; HEP G2 CELLS; HUMANS; MICE; MICE, NUDE; MUTATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RNA, SMALL INTERFERING; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE;

MUS MUSCULUS;

EID: 79951811144     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.464     Document Type: Article

References (45)

1. Anjum R, Blenis J. (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758.
2. Aranda A, Pascual A. (2001). Nuclear hormone receptors and gene expression. Physiol Rev 81: 1269-1304. (Pubitemid 32606670)
3. Aranda A, Martínez-Iglesias O, Ruiz-Llorente L, García-Carpizo V, Zambrano A. (2009). Thyroid receptor: roles in cancer. Trends Endocrinol Metab 20: 319-324.
4. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, Saatcioglu F. (2002). Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem 277: 49517-49522. (Pubitemid 36014389)
5. Bos JL. (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
6. Campbell SL, Khosravi-Far, Rossman KL, Clark GJ, Der CJ. (1998). Increasing complexity of Ras signaling. Oncogene 17: 1395-1413.
7. Castillo AI, Sanchez-Martinez R, Moreno JL, Martinez-Iglesias OA, Palacios D, Aranda A. (2004). A permissive retinoid X receptor/thyroid hormone receptor heterodimer allows stimulation of prolactin gene transcription by thyroid hormone and 9-cis-retinoic acid. Mol Cell Biol 24: 502-513. (Pubitemid 38057904)
8. Chan IH, Privalsky ML. 2006. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 25: 3576-3588. (Pubitemid 43901679)
9. Damm K, Beug H, Graf T, Vennströ m B. (1987). A single point mutation in erbA restores the erythroid transforming potency of a mutant avian erythroblastosis virus (AEV) defective in both erbA and erbB oncogenes. EMBO J 6: 675-682.
10. De Bosscher K, Van Craenenbroeck K, Meijer OC, Haegeman G. (2008). Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol 583: 290-302.
11. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ et al. (1998). Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280: 1747-1749. (Pubitemid 28283497)
12. Fernandez-Majada V, Pujadas J, Vilardell F, Capella G, Mayo MW, Bigas A et al. (2007). Aberrant cytoplasmic localization of N-CoR in colorectal tumors. Cell Cycle 6: 1748-1752. (Pubitemid 47327928)
13. Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ. (1994). Induction of cyclin D1 overexpression by activated ras. Oncogene 9: 3627-3633. (Pubitemid 24359401)
14. Flamant F, Baxter JD, Forrest D, Refetoff S, Samuels H, Scanlan TS et al. (2006). International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev 58: 705-711.
15. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS et al. (2005). An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25: 124-135. (Pubitemid 40039805)
16. Furuya F, Lu C, Guigon CJ, Cheng SY. (2009). Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids 74: 628-634.
17. Garcia-Silva S, Aranda A. (2004). The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol 24: 7514-7523. (Pubitemid 39121479)
18. Hong SH, Yang Z, Privalsky ML. (2001). Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 21: 7172-7182. (Pubitemid 32953471)
19. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R et al. (1995). Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397-404.
20. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A et al. (1998). Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27: 951-958. (Pubitemid 28160479)
21. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TMG, Schiff R et al. (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925.
22. Lazar MA. (2003). Nuclear receptor corepressors. Nucl Recept Signal 1: e001.
23. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, Yang-Yen HF. (1995). Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 15: 3654-3663.
24. Lowy DR, Willumsen BM. (1993). Function and regulation of ras. Annu Rev Biochem 62: 851-891. (Pubitemid 23237890)
25. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletterick RJ et al. (2002). TR surfaces and conformations required to bind nuclear receptor corepressor. Mol Endocrinol 16: 271-286. (Pubitemid 34131225)
26. Martínez-Iglesias O, García-Silva S, Tenbaun SP, Regadera J, Larcher F, Paramio JM et al. (2009a). The thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69: 501-509.
27. Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A. (2009b). Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One 4: e6428.
28. Meier CA, Dickstein BM, Ashizawa K, McClaskey JH, Muchmore P, Ransom SC et al. (1992). Variable transcriptional activity and ligand binding of mutant beta 1 3,5,3′-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol 6: 248-258.
29. Mendez-Pertuz M, Sanchez-Pacheco A, Aranda A. (2003). The thyroid hormone receptor antagonizes CREB-mediated transcription. EMBO J 22: 3102-3112. (Pubitemid 36758630)
30. Pascual G, Glass CK. (2006). Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17: 321-327. (Pubitemid 44397567)
31. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW et al. (1999). Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13: 3198-3208. (Pubitemid 30030442)
32. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL. (2007). The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27: 5933-5948. (Pubitemid 47333769)
33. Pfahl M. (1993). Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651-658.
34. Pissios P, Tzameli I, Kushner P, Moore DD. (2000). Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell 6: 245-253.
35. Privalsky ML. (2004). The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66: 315-360.
36. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P et al. (1998). Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12: 2469-2474. (Pubitemid 28406950)
37. Rogatsky I, Zarember KA, Yamamoto KR. (2001). Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20: 6071-6083. (Pubitemid 33049282)
38. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. (1998). Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem 273: 30175-30182. (Pubitemid 28545480)
39. Sanchez-Martinez R, Castillo AI, Steinmeyer A, Aranda A. (2006). The retinoid X receptor ligand restores defective signalling by the vitamin D receptor. EMBO Rep 10: 1030-1034. (Pubitemid 44480519)
40. Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S et al. (2005). Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res 65: 4554-4561. (Pubitemid 40740790)
41. Suzuki H, Willingham MC, Cheng SY. (2002). Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12: 963-969. (Pubitemid 35404130)
42. Tagami T, Madison LD, Nagaya T, Jameson JL. (1997). Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 17: 2642-2648. (Pubitemid 27175146)
43. Xing J, Ginty DD, Greenberg ME. (1996). Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273: 959-963. (Pubitemid 26275173)
44. Yen PM. (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142.
45. Zhu XG, Zhao L, Willingham MC, Cheng SY. (2010). Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29: 1909-1919.